In vivo

#Assays #Drug screening #In vivo #Promega

Five questions to answer before you move your assays from 2D to 3D 

This paid-for advertorial by Promega appeared in DDW Volume 27 – Issue 3, Summer 2026.   The shift from 2D monolayers to 3D cell culture models like spheroids, organoids, and complex tissue constructs, is gaining momentum in the drug discovery space. And for good reason: 3D models better recapitulate in vivo biology, improving the predictive value of early… Read More

#Exclusive Content

#In vivo #Pharmacology #Sygnature Discovery

Sygnature Discovery appoints new Head of In Vivo Pharmacology 

CRO Sygnature Discovery has announced the appointment of Susanne Back as Head of In Vivo Pharmacology.  Back has 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River. She will lead one of Sygnature’s in vivo pharmacology… Read More

#News

CAR T-cells attacking a cancer cell
#Bristol Myers Squibb #CAR-T #Cell therapy #In vivo #Mergers and acquisitions

BMS boosts cell therapy portfolio with Orbital acquisition

Bristol Myers Squibb has announced plans to acquire in vivo CAR-T company Orbital Therapeutics for $1.5 billion.  The acquisition includes Orbital’s lead RNA immunotherapy preclinical candidate currently in IND-enabling studies, OTX-201, which comprises an optimised circular RNA encoding a CD19-targeted CAR for in vivo expression delivered via targeted lipid nanoparticles… Read More

#Business & Investment #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #In vitro #In vivo

Navigating considerations for ADCs: Guidance for the industry

This paid-for advertorial from Eurofins appeared in DDW Volume 26 – Issue 4, Fall 2025   Antibody-drug conjugates (ADCs) are increasingly promising due to advances in biologics and chemistry. With 16 FDA-approved ADCs, clinical interest is growing, though development remains complex, requiring thorough evaluation of the antibody, linker, payload, and… Read More

#Exclusive Content

CAR-T cell attacking cancer
#CAR-T #Cell therapy #In vivo #Kite Pharma #Mergers and acquisitions

Kite acquires in vivo CAR-T developer for $350 million

Gilead-owned Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million.  The acquisition complements Kite’s focus on cell therapy by incorporating Interius’s integrating in vivo platform.   This approach enables the generation of CAR T-cells directly within… Read More

#Business & Investment #News

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #Haematology #In vivo #Lipid based nanoparticle (LNP) #NanoCell Therapeutics #Oncology

First non-viral DNA-based in vivo CAR-T generation

A new study has demonstrated the first stable, functional chimeric antigen receptor T-cells (CAR-T) cell generation in vivo using targeted lipid nanoparticles for DNA delivery.  The research evaluated NanoCell Therapeutics’ targeted lipid nanoparticle delivery system, termed NCtx, which enables the… Read More

#Cancer Research #News #Trending News

Human gastrointestinal tract
#Assays #Drug discovery #Guide #In vivo #Obesity #Weight loss

Guide: Accelerate your weight loss drug discovery

A new Guide is now available from Eurofins Discovery entitled ‘Drug Discovery for Anti-Obesity‘. Explore obesity case studies profiling semaglutide, tirzepatide, and retatrutide using Eurofins Discovery’s weight-loss solutions. Advance your obesity program with on/off-target panels, translational assays, in vivo models, and MOA-reflective tools. Partner with expert scientists and program… Read More

#News

Drug Discovery for Anti-Obesity
#Assays #Drug discovery #In vivo #Obesity #Weight loss

Accelerate your weight loss drug discovery

Explore obesity case studies profiling semaglutide, tirzepatide, and retatrutide using Eurofins Discovery’s weight-loss solutions. Advance your obesity program with on/off-target panels, translational assays, in vivo models, and MOA-reflective tools. Partner with expert scientists and program managers for strategic guidance and scientific leadership on your integrated drug discovery programs targeting weight-loss… Read More

#Resources

#AbbVie #Capstan Therapeutics #CAR-T #Cell therapy #In vivo #Mergers and acquisitions

AbbVie acquires in vivo CAR-T technology with Capstan purchase

AbbVie has revealed it will acquire Capstan Therapeutics, a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs.  The acquisition will include CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase I development for the treatment of B… Read More

#Business & Investment #News

Circular DNA concept
#Cell and gene therapy #Circio Holding #circular RNAs #In vitro #In vivo

Circular RNA technology could open new therapeutic opportunities

Circular RNA technology continues to demonstrate broad capability to significantly boost protein expression level and durability for both viral and non-viral gene and cell therapy, according to new data.  Circio Holding shared the new and strengthened in vivo data for its circVec platform at the… Read More

#News

Human adenovirus
#biological engineering #CAR-T #Cell and gene therapy #Cell therapy #EsoBiotec #In vivo

Revolutionising cancer treatment with viral vectors

CAR-T cell therapy has revolutionised cancer treatment, offering life-changing outcomes for patients with haematological malignancies. Jean-Pierre Latere, PhD, CEO of EsoBiotec, discusses advances in in vivo engineering, which are poised to overcome manufacturing and cost barriers, making these therapies more accessible and expanding their potential applications. The landscape of cancer… Read More

#Cancer Research #Exclusive Content

CAR-T in multiple myeloma
#CAR-T #Cell therapy #EsoBiotec #In vivo #Myeloma #Pregene Biopharma

In vivo BCMA CAR-T candidate shows promise in first human trial

EsoBiotec and Pregene Biopharma have dosed the first patient in an investigator-initiated clinical trial in China of ESO-T01 for relapsed/refractory multiple myeloma.   ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells.  The clinical… Read More

#Cancer Research #News

CAR-T therapy
#CAR-T #Cell therapy #EsoBiotec #In vivo #Myeloma #Phase I trial

First in vivo BCMA CAR-T candidate reaches the clinic

A clinical trial has launched in China of ESO-T01, an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into BCMA CAR-T cells, for the treatment of multiple myeloma.  The proof-of-concept, first-in-human trial is underway and initial clinical data are expected to be presented… Read More

#Editor's Choice #News

#Humanised Immune System (HIS) #In vivo #Mouse models #Preclinical development #Whitepaper

Whitepaper: Unlock drug discovery with HIS mouse models

Sophisticated in vivo models are paramount for evolving drug research and developing biologic therapeutics. A new whitepaper from Taconic Biosciences delves into the challenges faced by researchers in sourcing appropriate models and how humanized immune system (HIS) models can provide innovative solutions. You will learn about: The significance of… Read More

#News

#Humanised Immune System (HIS) #In vivo #Mouse models #Preclinical development

Unlocking drug discovery with humanized immune system mouse models

Sophisticated in vivo models are paramount for evolving drug research and developing biologic therapeutics. Our whitepaper delves into the challenges faced by researchers in sourcing appropriate models and how humanized immune system (HIS) models can provide innovative solutions. You will learn about: The significance of HIS models in bridging the… Read More

#Resources

A laboratory mouse
#Clinical trials #Drug toxicity #In vivo #Mouse models #Preclinical development #Whitepaper

How can you ensure a confident transition to human trials?

A new whitepaper is now available from The Jackson Laboratory, entitled ‘Evidence-based selection of the starting dose in first-in-human clinical trials using humanised mouse models‘. This paper discusses the challenges drug developers face when transitioning from preclinical discovery to clinical trials and proposes expanding the drug development… Read More

#News